Mutabilis
Mutabilis is discovery of new therapeutic targets for the development of anti-infectives. Mutabilis is a biopharmaceutical company specialised in the discovery and development of anti-infectives. Mutabilis discovers and develops innovative anti-infectives, a novel class of drug addressing the current issues arising from resistance to antibiotics and targeting severe bacterial infections. Mutabilis’ new therapies target nosocomial infections in particular.
Industries
biotechnology
Nr. of Employees
small (1-50)
Patents
Heterocyclic compounds and their use in preventing or treating bacterial infections
US-11865118-B2
View DetailsHeterocyclic compounds and their use in preventing or treating bacterial infections
US-11530227-B2
View DetailsHeterocyclic compounds and their use in preventing or treating bacterial infections
US-10842779-B2
View DetailsHeterocyclic compounds and their use in preventing or treating bacterial infections
US-10722520-B2
View DetailsHeterocyclic compounds and their use in preventing or treating bacterial infections
US-10570131-B2
View DetailsHeterocyclic compounds and their use in preventing or treating bacterial infections
US-10501481-B2
View Details
Heterocyclic compounds and their use in preventing or treating bacterial infections
US-11865118-B2
View DetailsHeterocyclic compounds and their use in preventing or treating bacterial infections
US-11530227-B2
View DetailsHeterocyclic compounds and their use in preventing or treating bacterial infections
US-10842779-B2
View DetailsHeterocyclic compounds and their use in preventing or treating bacterial infections
US-10722520-B2
View DetailsHeterocyclic compounds and their use in preventing or treating bacterial infections
US-10570131-B2
View DetailsHeterocyclic compounds and their use in preventing or treating bacterial infections
US-10501481-B2
View Details